FEIBA-GO
Research type
Research Study
Full title
FEIBA NF GLOBAL OUTCOME STUDY
IRAS ID
164731
Contact name
Senta Habenicht
Contact email
Sponsor organisation
Baxalta Innovations GmbH
Duration of Study in the UK
5 years, 4 months, 29 days
Research summary
The study addresses the need to measure long-term effectiveness, safety and quality of life outcome measures for haemophilia A or B patients with high-responding inhibitors treated on-demand and in prophylaxis with FEIBA NF [Anti-Inhibitor Coagulant Complex].
The purpose of the study is to document the natural history of haemophilia A or B disease in subjects with high responding inhibitors either to Factor VIII or Factor IX and to describe long-term outcomes in terms of effectiveness, safety and quality of life in subjects receiving FEIBA NF in routine clinical practice.REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
15/EM/0258
Date of REC Opinion
31 Jul 2015
REC opinion
Further Information Favourable Opinion